Online inquiry

IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5425MR)

This product GTTS-WQ5425MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD74 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001025158.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 972
UniProt ID P04233
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5425MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11370MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ15184MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ1984MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ2904MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG827
GTTS-WQ8610MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ2643MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ10317MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ15853MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb5871
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW